Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ: TELO )

4.430 +0.230 (+5.48%)
Streaming Delayed Price Updated: 1:14 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 163,658
Open 4.470
Bid (Size) 4.420 (2)
Ask (Size) 4.460 (2)
Prev. Close 4.200
Today's Range 4.410 - 4.948
52wk Range 3.110 - 20.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
Via Investor Brand Network
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Via ACCESSWIRE

Performance

YTD
-11.40%
-11.40%
1 Month
+2.31%
+2.31%
3 Month
-18.57%
-18.57%
6 Month
-20.89%
-20.89%
1 Year
-11.40%
-11.40%

More News

Read More
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
Via Investor Brand Network
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Via ACCESSWIRE
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Via News Direct
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Via ACCESSWIRE
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
Via Investor Brand Network
Exposures Product Safety
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Via ACCESSWIRE
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
Via News Direct
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.